IMMUNOSABR

ImmunoSABR combines two treatment strategies: stereotactic radiotherapy (SABR) and immunotherapy, a "1+1=3" combination. Clinical studies on immunotherapy have shown increasingly good responses. Immunotherapy is also standard of care in certain conditions as a first line or second line treatment. SABR and immunotherapy are a "1+1=3" combination, by first providing, in several preclinical models) a strong synergistic and complementary effect by exploiting the clinical detectable cancer lesions as an ‘in situ' vaccine by SABR in order to enhance systemic anti-tumour immune responses to target synchronous micrometastases, and second boosting effective tumour-specific immunity for long term tumour control (the so-called "memory effect")... Metastatic cancer is responsible for 90% of cancer deaths Metastatic cancer is responsible for 90% of cancer deaths worldwide. Non-small cell lung cancer (NSCLC) comprises 85% of all lung cancer cases. The majority of patients are diagnosed at the time..

Primary location: Maastricht Netherlands